UK first in Europe to approve Valneva's easy-store COVID-19 vaccine
![](/46/pdcnewsitem/11/71/94/covid vaccine.jpg)
The UK was the first European country to approve the vaccine from French firm Valneva
The UK has approved a new COVID-19 vaccine from French biotech Valneva that is easier to store than market rivals and involves a process widely used in making flu and polio vaccines.
The VLA2001 vaccine is whole-virus inactivated, meaning the virus is grown in a lab and then made completely inactive so that it cannot infect cells or replicate in the body, but can still trigger an immune response. It received conditional marketing authorisation from the UK medicines regulator on Thursday for use by people aged 18-50.
Unlike many other COVID-19 vaccines which require ultra-cold storage, VLA2001 can be stored in temperatures achievable with a domestic refrigerator.
The European Medicines Agency’s human medicines committee (CHMP) initiated a rolling review of VLA2001 in December, 2021 and is expected to come to a decision this month. Valneva said in March that it expects a positive EMA recommendation, adding it has started manufacturing and has inventory ready for labelling and deployment once approved.
The company signed an advance purchase agreement with the European Commission for up to 60 million doses in November last year, with plans to deliver 24.3 million doses during the second and third quarters of 2022.
If approved, the shot would be the first inactivated whole-virus vaccine against COVID-19 in Europe. The technology has been used for decades, including in some vaccines against polio, influenza as well as the hepatitis A. Some view it as having the potential to appeal to those wary of new mRNA technology.
The vaccine was granted emergency use authorization by Bahrain’s health regulator at the beginning of March, having also signed an advance purchase agreement.
Related News
-
News mRNA therapy for ovarian cancer and muscle wasting
Researchers demonstrate results of a promising mRNA therapy for ovarian cancer and muscle wasting caused by cachexia, a condition associated with various types of cancers and chronic diseases. -
News Pfizer CentreOne Content Refinement Q3 media buy
For 40 years Pfizer CentreOne has been guiding drug projects to success. Here’s how our services make us an altogether different kind of CDMO: -
News Bora Pharmaceuticals expands development and manufacturing capacity with landmark acquisition
Taiwan-based CDMO Bora Pharmaceuticals have acquired niche generic drugs developer TWi Pharmaceuticals, expanding their outsourced development and manufacturing services with two additional manufacturing facilities. -
News Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Through a collaboration with biotech company Touchlight, Lonza is set to expand their end-to-end offering for mRNA manufacturing with additional DNA raw material sources, including Touchlight’s doggybone DNA. -
News Oxford University presents promising phase II data for malaria vaccine
The malaria vaccine R21/Matrix-M, developed by researchers at Oxford University, has produced encouraging new data for the global effort against the mosquito-borne disease. -
News NextPharma to acquire Norway manufacturing site from Takeda
Biopharmaceutical company Takeda and CDMO NextPharma have announced an acquisition agreement in which Takeda will divest from their Asker, Norway manufacturing site, set to be acquired by NextPharma. -
News Gut instinct: molecular link between COVID-19 and serotonin cells in the gut
New research may provide further evidence of the gut’s role in SARS-CoV-2 infection and disease severity with a molecular link between serotonin-producing cells in the gut and COVID-19 disease severity. -
News Novavax COVID-19 vaccine receives backing from European Medicines Agency
The European Medicines Agency has backed the Nuvaxovid COVID-19 vaccine for adults as a booster shot to other COVID-19 vaccines.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance